[Effects of pinyangmycin, dexamethasone and sodium morrhuate injection on treatment of cavernous hemangioma in maxillofacial regions].
OBJECTIVE
To evaluate the effects of Pinyangmycin, Dexamethasonum and Sodium morrhuate injected homochronouly on treatment of cavernous hemangioma in maxillofacial regions.


METHODS
The medical records of 115 patients with cavernous hemangioma in maxillofacial regions between September, 1996 and September, 1998 were reviewed. Fifty of the patients were men, and 65 were women, with a ratio of 1:1.3. The age of the patients was from 4 months old to 45 years old. 73 of the hemangioma bodies were sited in maxillofacial regions, 42 were sited in oral cavity. The sizes of the lesions varied from 1 cm x 1 cm to 5 cm x 8 cm. Treatment procedure: 1. Preparation: 8 mg Pinyangmycin was dissolved in 5 mg/ml Dexamethasonum and in 4 ml of 1% procain which were ready for use; 2. Injection: 1-5 ml (Pinyangmycin 1.6-8.0 mg) of mixed solution was first injected to the hemangioma, then followed by an injection of 0.5-2.0 ml Sodium morrhuate according to local appearance, size of the tumor and patient's age. Generally, the amount of each injection should not be over 8 mg Pinyangmycin. If the tumor did not subside after an injection, another injection might be repeated every 5-7 days, and this process might be repeated 3-5 times. The total dose of Pinyangmycin should not be over 40 mg.


RESULTS
115 patients were followed up for 6-24 months. 81 of 115 (70.43%) cases were recovered, and 30 (26.09%) cases were basically recovered. 4 (3.48%) cases got improvement. The recovery rate were 96.52%, and the total efficiency was 100%.


CONCLUSIONS
This method may be a safe, simple and effective therapy to cavernous hemangioma in maxillofacial regions.
Shou
B
B
Department of Stomatology, Nanjing General Hospital of PLA.
Meng
Z
Z
Yang
Z
Z
Zhang
Z
Z
Xu
J
J
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002648:Child; D002675:Child, Preschool; D003907:Dexamethasone / Q000008:administration & dosage; D005153:Facial Neoplasms / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006392:Hemangioma, Cavernous / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D015552:Injections, Intralesional; D007573:Jaw Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009918:Orbital Neoplasms / Q000188:drug therapy; D012976:Sodium Morrhuate / Q000008:administration & dosage
D001761:Bleomycin; C021771:zhengguangmycin; D003907:Dexamethasone; D012976:Sodium Morrhuate